J&J Said to Pay $2.2 Billion to End Risperdal Sales Probe

Johnson & Johnson has agreed to pay as much as $2.2 billion to settle U.S. probes of the marketing of its Risperdal antipsychotic drug and other medications, two people familiar with the negotiations said. The settlement, which might be announced this week, will include a misdemeanor plea and criminal penalty of as much as $600 million. The accord also would resolve civil claims that J&J paid kickbacks to Omnicare Inc., a company that dispenses drugs at nursing homes, the people said.

Read more about the Risperdal settlements…

0 Responses to “J&J Said to Pay $2.2 Billion to End Risperdal Sales Probe”



  1. Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s




Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 434 other followers

Contact Us:

Hissey Kientz, LLP

9442 Capital of Texas Hwy N.

Arboretum Plaza One, Suite 400

Austin, Texas 78759

Toll-free: (866) 275-4454

Facsimile: (512) 320-9101

Email: info@hkllp.com

Sponsored By:

Hissey Kientz, LLP (Austin, TX)

Attorney Michael Hissey is responsible for the content of this website.


%d bloggers like this: